Translate Bio, Inc. Common Stock
TBIO
TBIO was delisted on the 13th of September, 2021.
34 hedge funds and large institutions have $227M invested in Translate Bio, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 34 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$76.3M |
| 2 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$29.5M |
| 3 |
BG
Baupost Group
Boston,
Massachusetts
|
+$23.2M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$12.2M |
| 5 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$11.8M |
Top Sellers
TBIO Hedge Fund Activity: Q2 2018 in Review
34 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Translate Bio, Inc. Common Stock (TBIO) for Q2 2018, worth a combined $227M.
Buyers outnumbered sellers: 34 funds opened new TBIO positions and 0 closed out — a net gain of 34 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $76.3M.
- 34 institutional investors held Translate Bio, Inc. Common Stock (TBIO) as of Q2 2018, up from 0 in Q1 2018.
- Funds reported $227M of Translate Bio, Inc. Common Stock stock for Q2 2018.
- 34 funds opened new Translate Bio, Inc. Common Stock positions in Q2 2018 and 0 closed out, a net change of +34 holders.
- The largest Translate Bio, Inc. Common Stock buyer in Q2 2018 was Fidelity Investments, an estimated $76.3M added.
Based on aggregated 13F filings for Q2 2018.